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OBJECTIVES This study was designed to determine the characteristics and outcomes of spontaneous
conversion (SC) to sinus rhythm (SR) in patients with atrial fibrillation (AF) of more than
two days.
BACKGROUND The Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE)
multicenter study was a prospective trial in which transesophageal echocardiography (TEE)-
guided treatment was compared with conventional anticoagulation treatment for the
management of patients with AF2 days undergoing direct current cardioversion (DCC). In
an ancillary analysis, we evaluated the baseline and outcome data in patients who underwent
SC to SR before scheduled DCC.
METHODS We identified 1,041 patients for this analysis after excluding patients on pre-existing
antiarrhythmic agents. Patients with SC in the TEE-guided and conventional groups were
first compared then pooled and compared with non-spontaneous conversion (No-SC)
patients.
RESULTS Overall, 167 of 1,041 (16%) patients underwent SC, with twice as many in the conventional
compared with the TEE-guided group (110/523 [21%] vs. 57/518 [11%]; p  0.001). When
compared with No-SC patients, a higher proportion of SC patients maintained SR at eight
weeks (87.2% vs. 48.9%, p  0.001), without statistically significant differences in bleeding,
thromboembolism or mortality. Multivariate predictors of SC were shorter duration of AF,
New York Heart Association (NYHA) functional class 1 or 2, smaller left atrial size, and
absence of left atrial spontaneous echo contrast.
CONCLUSIONS Spontaneous conversion was associated with shorter duration of AF, lower NYHA class,
smaller left atrial size, and absence of left atrial spontaneous echo contrast. There was a better
SR outcome in the SR group, but no differences in the other clinical end points. The
conventional treatment strategy allowed greater opportunity for SC. In the absence of
favorable predictors of SC, the TEE-guided approach should be considered. (J Am Coll
Cardiol 2003;42:1638–43) © 2003 by the American College of Cardiology Foundation
The Assessment of Cardioversion Using Transesophageal
Echocardiography (ACUTE) multicenter study was a
prospective randomized trial in which transesophageal
echocardiography (TEE)-guided treatment with short-term
anticoagulation was compared with a conventional antico-
agulation strategy for the management of patients with
atrial fibrillation (AF) 2 days undergoing electrical car-
dioversion. The ACUTE study demonstrated that a TEE-
guided cardioversion with short-term anticoagulation was a
safe and clinically effective alternative to the conventional
approach (1). It was also recognized, especially in the
conventional group, that before scheduled cardioversion, a
significant proportion of patients in the study underwent
spontaneous conversion (SC) to sinus rhythm (SR).
Management options in hemodynamically stable patients
with AF 48 h include initiation of rate control with
anticoagulation alone (2) or electric or pharmacologic car-
dioversion with either the conventional anticoagulation or
TEE-guided strategies. However, all these approaches can
be associated with significant morbidity and mortality (2–4)
as well as bleeding and thromboembolic complications. In
patients with AF 48 h, waiting for SC may be the most
cost-effective option (5), although SC has also been associ-
ated with complications (6–8). Therefore, identification of
patients likely to undergo SC may be important in order to
direct appropriate therapy and to postpone pharmacologic
or electric cardioversion.
There has not been a large prospective multicenter study
evaluating SC in patients with AF of 2 days duration.
Therefore, in the ACUTE study, we performed an ancillary
analysis to: 1) determine the incidence of SC; 2) outline
characteristics and outcomes of SC patients between the
TEE-guided and conventional groups; and 3) compare the
pooled SC patients to pooled non-spontaneous conversion
(No-SC) patients. We also sought to determine indepen-
dent predictors of SC to more accurately identify patients
likely to undergo SC.
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METHODS
In the ACUTE study, 1,222 patients were enrolled between
August 6, 1994, and August 18, 1999, from 70 sites. The
methods have been fully described elsewhere (1,9). In brief,
patients were enrolled and randomized to either a strategy of
treatment guided by the findings of TEE with short-term
anticoagulation, or a conventional treatment strategy of
anticoagulation (Fig. 1). Patients randomized to the TEE-
guided group were therapeutically anticoagulated before
electrical direct-current cardioversion (DCC). Inpatients
were typically treated with intravenous unfractionated hep-
arin (target activated partial thromboplastin time  1.5 to
2.5 times control) and outpatients received warfarin (target
international normalized ratio  2.0 to 3.0). Using TEE,
the patients were then stratified on the basis of the presence
or absence of thrombus. Patients assigned to the conven-
tional group received three weeks of therapeutic warfarin
therapy prior to cardioversion, followed by a four-week
period of post-cardioversion warfarin according to the
American College of Chest Physicians (ACCP) guidelines.
Full details of anticoagulation and patients monitoring have
been previously described (9).
The institutional review board of each participating
medical center approved the protocol and informed consent
was obtained from each trial participant.
Patients. In the ACUTE study, patients who were candi-
dates for electrical cardioversion and at least 18 years old
with AF for at least 2 days were eligible for enrollment.
Similar patients with atrial flutter and a history of AF were
also eligible. Hemodynamically unstable patients and those
with pure atrial flutter without a history of AF were
excluded. All patients were enrolled in an intention-to-treat
analysis and followed from enrollment to day 56 when end
points were assessed.
For the purposes of this ancillary study, patients who
underwent SC to SR before DCC were identified as SC
patients. All other patients who underwent DCC or chem-
ical cardioversion were classified as No-SC. Patients on
pre-existing Vaughn-Williams Class 1 or 3 antiarrhythmic
agents before enrollment were excluded from the analysis.
The resulting study population was 1,041 patients. Baseline
characteristics and outcomes of SC were first compared
between the TEE-guided and conventional groups before
the entire patient cohort was pooled and evaluated by SC
and No-SC patient subgroups. The study protocol is illus-
trated in Figure 1.
Outcomes. Outcomes assessed in this analysis were embo-
lism, which was a composite of cerebrovascular accidents,
transient ischemic attacks, and peripheral embolism; all-
cause mortality; major or minor bleeding complications;
functional status (measured by the Duke Activity Status
Index); and success or maintenance of SR. Additional
outcomes of this ancillary analysis were time to spontane-
ously convert from enrollment and independent multivariate
predictors of SC.
Statistical analysis. In the univariate analysis, data are
expressed as mean  SD, as medians with interquantile
ranges or as frequencies or percentages with 95% confidence
intervals. Chi-square tests were used for the comparison of
categorical variables in the treatment groups. Wilcoxon
Abbreviations and Acronyms
ACUTE  Assessment of Cardioversion Using
Transesophageal Echocardiography study
AF  atrial fibrillation
DCC  direct-current cardioversion
LA  left atrial
LVEF  left ventricular ejection fraction
No-SC  non-spontaneous conversion
NYHA  New York Heart Association
SC  spontaneous conversion
SR  sinus rhythm
TEE  transesophageal echocardiography
TTE  transthoracic echocardiogram
Figure 1. Branch tree diagram illustrating enrollment and assignment of
Assessment of Cardioversion Using Transesophageal Echocardiography
(ACUTE) patients and how patients with spontaneous conversion to sinus
rhythm were identified for the analysis. Patients were randomly assigned to
either the transesophageal echocardiogram (TEE)-guided or conventional
treatment groups. In the TEE arm, patients who underwent SC either
before TEE-guided direct current cardioversion (DCC) or who had no
TEE were enrolled in the ancillary study. In the conventional arm, patients
who underwent SC before DCC were enrolled. Patients who were in the
DCC not-done category and did not have spontaneous conversion had
other outcomes such as medical complications, surgery, or thrombi or were
not therapeutically anticoagulated. AAA*  antiarrhythmic agents:
Vaughn-Williams type 1 and 3; patients on these agents were excluded
from the analysis.
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two-sample test was used for the comparison of continuous
variables. Potential predictors of SC were assessed using
multivariate logistic regression with stepwise selection with
SAS software (SAS/STAT release 8.2, 2000; SAS Institute
Inc., Cary, North Carolina). One thousand bootstrap sam-
ples (random sample of 80% of the total with replacement)
were used in the analysis for identification of clinical and
echocardiographic predictors. Variables with high frequency
(50% or higher) of being a predictor in individual bootstrap-
ping were selected for a final model. Receiver-operating
characteristic curve were used to identify the optimal AF
duration and left atrial (LA) size. The results are expressed
as the area under the curve with 95% confidence intervals.
All statistical testing was conducted at a significance level of
0.05 with a two-tailed alternative hypothesis.
RESULTS
TEE-guided vs. conventional treatment groups. Out of
the total 1,041 patients, 167 (16%) underwent SC to SR: 57
in the TEE-guided group and 110 in the conventional
group. Table 1 compares the baseline characteristics of
patients in the TEE-guided and conventional groups who
underwent SC to SR. Almost twice as many conventional
group patients underwent SC compared with the TEE-
guided group (21% vs. 11%, p 0.001) although there were
no differences in age, functional status, and proportion of
patients with atrial flutter, or median estimated duration of
AF. Table 1 also shows the outcomes of the SC patients in
the TEE-guided and conventional groups at eight weeks.
There were no statistically significant differences in inci-
dence of composite embolism, major or minor bleeds,
functional capacity, mortality or maintenance of SR at eight
weeks between the treatment groups of the study for
patients who underwent SC.
SC versus No-SC. Patients who underwent SC to SR in
both the TEE-guided and conventional groups were pooled
and compared to the No-SC patients. Table 2 illustrates the
baseline characteristics of the two groups. There were no
differences in age, rhythm at enrollment, or functional status
in the two groups. However, SC patients had smaller mean
LA size (22.7  7.9 cm2 vs. 26.2  9.3 cm2, p  0.001),
higher mean left ventricular ejection fraction (LVEF) (53.2
 13.8 vs. 50.1 15.5, p 0.02), shorter median estimated
duration of AF before enrollment (8 vs. 14 days, p 0.001)
and tended to have a lower frequency of congestive heart
failure (22.4% vs. 29.9%, p  0.06). However, a higher
proportion of SC patients used calcium channel blockers
(39.4% vs. 29.9%, p  0.02) but a lower proportion used
digoxin (46% vs. 57%, p  0.01).
Table 2 also shows outcomes of patients in the SC and
No-SC groups. There was a higher maintenance of SR in
SC patients at eight weeks compared with No-SC (87.2%
vs. 48.9%, p  0.001). However, there were no differences
in functional capacity, composite embolism, bleeding, or
mortality between SC and No-SC patients.
Duration of pre-existing AF and time to SC. The dura-
tion of pre-existing AF in patients ranged from 2 to 453
days. Figure 2 illustrates SC rates as related to duration of
pre-existing AF at enrollment in weeks. The majority of
patients (51%) who underwent SC had a history of one
week or less of AF. As AF duration increased, the propor-
tion of patients with SC decreased.
Spontaneous conversion patients converted earlier to SR
after enrollment when compared with No-SC (median
duration 4 days, interquantile range 1 to 19 days vs. 7 days,
interquantile range 1 to 29 days), and reflected the trend of
early achievement of SR (p  0.09). Figure 3 illustrates the
proportion of patients who underwent SC to SR in the first
week following enrollment. The highest proportion of
patients (41 patients, 24.5%) underwent SC to SR in the
first day of enrollment. Because TEE-guided patients were
cardioverted earlier due to study design (3 days vs. 31 days)
Table 1. Baseline Characteristics and 8-Week Outcomes of Patients in the TEE-Guided and
Conventional Groups Who Underwent Spontaneous Conversion
Variable
TEE-Guided
n  57
Conventional
n  110 p Value
Baseline Characteristics
Age (yrs) 63.9  13.2 64.3  13.5 0.71
Functional status, DASI score 31.9  18.0 29.6  17.5 0.41
LVEF (%) 54.3  12.8 52.5  14.4 0.64
LA size (cm2) 23.5  10.9 22.6  7.1 0.82
NYHA functional class 3 or 4 4 (7.0) 10 (9.1) 0.77
Patients with previous cardioversion 6 (10.3) 5 (4.5) 0.18
Atrial flutter 3 (5.3) 6 (5.5) 0.96
AF duration, median days (interquantile range) 7 (3–23) 8 (4–20) 0.43
Outcomes
Composite embolism 1 (1.7) 0 0.34
Composite bleeds 2 (3.5) 5 (4.5) 0.75
Mortality 1 (1.7) 0 0.34
Sinus rhythm at 8 weeks 46/56 97/108 0.22
Plus-minus values are means  SD, Interquartile ranges are 25% to 75%, number of patients (%).
AF  atrial fibrillation; DASI  Duke activity status index, range from 0 to 58.2 with higher scores indicating better
function; LA  left atrial; LVEF  left ventricular ejection fraction; NYHA  New York Heart Association; TEE 
transesophageal echocardiography.
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(1), more TEE-guided patients underwent SC in the first
week than conventional patients.
Multivariate predictors of SC. Controlling for other vari-
ables using a logistic regression model, several variables were
statistically significant as independent predictors of SC as
illustrated in Table 3.
Clinical predictors were shorter duration of pre-existing
AF (p  0.0001) and the presence of New York Heart
Association (NYHA) functional class 1 or 2 functional
classification (p 0.04). Echocardiographic predictors were
smaller LA size measured by two-dimensional transthoracic
echocardiogram (TTE) planimetry (p  0.0001) and ab-
sence of LA spontaneous echo contrast (p  0.01).
Receiver-operating characteristic curves were used to deter-
mine the optimal atrial size and duration of pre-existing AF
associated with SC. In the case of LA size, this was 23.3
cm2 (C-statistic or area under the curve  0.64, 95%
confidence interval 0.59 to 0.69, p  0.001). The optimal
duration of pre-existing AF associated with SC was nine
Figure 3. Proportion of patients who underwent spontaneous conversion
(SC) to sinus rhythm in the first week following enrollment. The bars
represent the proportion of patients who underwent SC to sinus rhythm on
a particular day and are subdivided into transesophageal echocardiography-
guided (TEE) (striped bars) and conventional (speckled bars) groups.
Most patients underwent SC in the first day following enrollment.
Table 2. Comparison of Baseline Characteristics and Eight-Week Outcomes of Patients in the
SC and NO-SC Groups
Variable
SC
n  167
No-SC
n  874 p Value
Baseline characteristics
Age (yrs) 64.2  13.4 64.9  13.3 0.38
Functional status (DASI) 30.4  17.6 28.5  17.3 0.17
LVEF (%) 53.2  13.8 50.1  15.5 0.02
LA size (cm2) 22.9  8.7 26.2  9.0  0.001
NYHA functional class 3 or 4 14 (8.4) 142 (16.2)  0.01
Rate-controlling agent*
Beta-blockers 39/165 (23.6) 209/835 (25.0) 0.76
Calcium-channel blockers 65/165 (39.4) 250/834 (29.9) 0.02
Digoxin 76/165 (46) 478/838 (57) 0.01
Patients with previous attempt at cardioversion 11 (15.6) 77 (8.4) 0.37
CHF 37/165 (22.4) 253/844 (29.9) 0.06
Duration of pre-existing atrial fibrillation,
median days (interquantile range)
8 (4–20) 14 (5–56)  0.01
Outcomes
Composite embolism 1 (0.6) 7 (0.8) 0.78
Composite bleeds 7 (4.2) 35 (4.0) 0.83
Mortality 1 (0.6) 16 (1.8) 0.49
SR at 8 weeks 143/164 (87.2) 383/782 (48.9)  0.001
DASI at 8 weeks 32.3  17.3 30.0  16.7 0.13
*Vaughn-Williams classification. Plus-minus values are means  SD, interquartile ranges are 25% to 75%, number of patients
(%).
CHF  congestive heart failure; No-SC  non-spontaneous cardioversion; SC  spontaneous conversion; SR  sinus
rhythm. Other abbreviations as in Table 1.
Figure 2. Frequency of patients who underwent spontaneous conversion
(SC) to sinus rhythm related to duration of pre-existing atrial fibrillation
(AF) prior to enrollment. This graph shows patients with pre-existing AF
of one week or less were more likely to have SC. Less than 10% of the SC
patients had pre-existing AF more than 12 weeks (not shown).
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days or less (C statistic or area under the curve 0.61, 95%
confidence interval 0.56 to 0.68, p  0.001).
DISCUSSION
Although patients with AF have been reported to sponta-
neously convert to SR, this has not been prospectively
investigated in patients with AF 48 h duration. Our SC
ancillary study in the ACUTE multicenter study is the
largest to date on SC and showed the following: 1) SC
occurred in 16% of patients studied; 2) there were no
differences in adverse clinical outcomes between patients in
the TEE or conventional groups that underwent SC; 3)
patients who underwent SC were more likely to have a
shorter duration of pre-existing AF and undergo conversion
to SR earlier; 4) SC patients were more likely to have a
higher LVEF and smaller LA size and less likely to have
congestive heart failure; 5) patients who underwent SC had
no difference in thromboembolism, bleeding or mortality
but a higher proportion was in SR at eight weeks compared
with No-SC patients; and 6) independent predictors of SC
were shorter duration of pre-existing AF, NYHA functional
class 1 or 2, smaller LA size (23.3 cm2), and absence of
LA spontaneous echo contrast.
In our prospective study, patients in the TEE-guided
group were noted to have a lower rate of SC compared with
the conventionally treated patients (11% vs. 21%), which
may reflect the study design, because patients in the TEE
arm were cardioverted much sooner (3 days vs. 31 days) (1).
The overall rate of SC (16%) was much lower than
reported in previous studies where rates of SC have been
derived from studies on chemical cardioversion of AF. In
previous studies, SC rates have also varied according to the
duration of pre-existing AF. In one study involving digoxin,
SC rates were 44% in patients with AF up to 7 days (10).
However, SC rates were as high as 72% in patients with AF
of 24 h or less in a study involving amiodarone (11). In a
goat model of artificially induced AF, it was demonstrated
that the likelihood of successful conversion to normal SR
diminished with increasing duration of AF (12). On the
other hand, in our study the duration of pre-existing AF
ranged from 2 days up to 453 days, thus accounting for the
relatively low SC rate. However, in patients with AF of 1
week or less, the SC rate of 51% compares favorably with
that of patients who underwent SC in the digoxin study
(10).
A higher proportion of SC patients maintained SR at
eight weeks, which may reflect a smaller LA size at baseline
and a shorter median duration of pre-existing AF. Despite
generally better baseline health of SC patients, there were
no differences in incidence of thromboembolism, mortality,
or bleeding complications when compared with No-SC
patients. However, the incidence of adverse events was low
and the study lacked adequate statistical power to suggest
equivalence for these end points in this ancillary study.
Certain clinical and echocardiographic variables have
been reported to be associated with a higher likelihood of
SC (13,14). The finding of a smaller LA size being
associated with greater success of conversion to SR in our
study concurs with some previous studies (14), but not with
others (15). Dittrich et al. (16) did not demonstrate any
correlation between success or maintenance of SR and LA
size, but this was a small retrospective study in which LA
size was assessed by M-mode echocardiography. It has been
demonstrated in previous studies that persistent AF leads to
progressive atrial enlargement (17), which may in turn
reduce the likelihood of conversion to SR (18). Our study
was larger than previous ones investigating the role of LA
size. We also measured LA size by two-dimensional TTE
planimetry and we believe our data are consistent with
pathophysiologic evidence from both human and animal
studies. We could not replicate normal LVEF as an inde-
pendent positive predictor of SC, which has been reported
in some studies; this may have been due to limitations in our
sample size and statistical power. An additional indepen-
dent predictor of SC was NYHA functional lass 1 or 2 that
may reflect patients with less severe forms of congestive
heart failure with better left ventricular function who may
have smaller atria, thus making SC more likely. Patients
with a shorter history of pre-existing AF were more likely to
undergo SC and that is consistent with previous studies
(10,11).
Study limitations. The ACUTE study was not primarily
designed to assess SC even though SC was a predetermined
outcome. The number of SC patients in the TEE-guided
group may have been underestimated because patients
without thrombus in this group were cardioverted sooner
due to study design. Thus, they were not given time to
undergo SC. This study was limited to patients with AF of
least 48 h duration and may not be applicable to patients
with a shorter history of AF. Although a statistically
significant higher proportion of SC patients were on
calcium-channel blockers, studies have shown that these
agents are effective in rate control only (19,20) and in some
cases may even reduce the likelihood of SC (21). However,
other studies have suggested that verapamil may reduce
recurrence of AF following electrical DCC in patients (22).
It is thus unclear whether calcium-channel blockers had any
influence on the higher spontaneous conversion rates in our
study.
Table 3. Logistic Regression Multivariate Independent
Predictors of Spontaneous Conversion to Sinus Rhythm
Predictor p Value
OR
(95% Confidence Limits)
Shorter duration of atrial
fibrillation
 0.0001 2.63 (1.3–5.47)
New York Heart Association
functional class 1 or 2
0.04 1.85 (1.02–3.34)
Smaller left atrial size  0.0001 2.2 (1.39–3.52)
Absence of spontaneous echo
contrast
0.01 6.74 (2.79–16.25)
OR  odds ratio.
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Clinical implications. In hemodynamically stable patients
with AF of at least 48 h duration with favorable predictors
of SC, it is not unreasonable to recommend that conven-
tional treatment of rate control and anticoagulation be
initiated while waiting for SC to occur, rather than per-
forming TEE-guided DCC. Such predictors include a
better NYHA functional class, shorter duration of pre-
existing AF, smaller LA size, and absence of LA spontane-
ous echo contrast. This approach may result in performing
fewer procedures (TEE and DCC), with potential cost
savings. On the other hand, in the absence of favorable
predictors it may be prudent to proceed to TEE-guided
DCC rather than wait for SC. In our study, the majority of
patients underwent SC in the first four days following
enrollment, although the decision when to proceed to
TEE-guided cardioversion should be individualized de-
pending on the status of the patient.
Conclusions. In the ACUTE trial ancillary study, SC
occurred in 16% of patients and was associated with shorter
duration of AF, lower NYHA class, smaller LA size and
absence of spontaneous echo contrast. There was a better
SR outcome in the SC group; however, there were no
differences in embolism, bleeding, and mortality between
the two groups. The conventional treatment strategy al-
lowed greater opportunity for SC. In the absence of favor-
able predictors of SC, the TEE-guided approach should be
considered rather than waiting for SC.
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APPENDIX
For a list of the participating ACUTE trial investigators and
centers, please see the November 5, 2003, issue of JACC at
www.cardiosource.com/jacc.html.
1643JACC Vol. 42, No. 9, 2003 Tejan-Sie et al.
November 5, 2003:1638–43 Spontaneous Conversion in AF
